Results 101 to 110 of about 18,115 (178)

Regorafenib for the treatment of hepatocellular carcinoma

, 2018
Hepatocellular carcinoma (HCC) is a worldwide problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized countries as well.
Bolondi, L, Tovoli, F, F. Tovoli, Granito, A, A. Granito, S. De Lorenzo, De Lorenzo, S, L. Bolondi   +7 more
core   +1 more source

LncRNA Impact on Regorafenib Resistance in Colorectal Cancer [PDF]

Cancer metastasis is one of the deadliest aspects of the disease, with about 90% of all cancer-related deaths due to its development at different sites within the body. Colorectal cancer (CRC) is the second leading cause of cancer mortality in the United
Leslie, Sophia, Pequeno Bracho, Ricardo, Hussain, Mohammad Shabir, Abuchard Anaya, Yamile, Doxtater, Kyle, Tripathi, Manish, Kwabiah, Dennis   +6 more
core   +1 more source

Management of regorafenib-related toxicities: a review

, 2015
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1 ...
Saravanan K. Krishnamoorthy, Vijay Jayaraman, Sunit Sebastian, Valerie Relias, Muhammad Wasif Saif   +4 more
core   +1 more source

Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study

Cancer Control
Purpose To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with regorafenib (hereafter, TACE-regorafenib) or camrelizumab (hereafter, TACE-camrelizumab) for treating hepatocellular carcinoma (HCC) with untreatable ...
Yanqiao Ren PhD, Yiming Liu PhD, Songlin Song PhD, Chuansheng Zheng PhD   +3 more
doaj   +1 more source

Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice

, 2018
Regorafenib has been demonstrated in our previous study to trigger apoptosis through suppression of extracellular signal-regulated kinase (ERK)/nuclear factor-κB (NF-κB) activation in hepatocellular carcinoma (HCC) SK-Hep1 cells in vitro.
Mao-Chi Weng, Yu-Cheng Kuo, Mei-Hui Wang, Hsin-Ell Wang, Jai-Jen Tsai, Yu-Chang Liu, Fei-Ting Hsu   +6 more
core   +1 more source

Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research
Background Hepatocellular carcinoma (HCC) presents a significant therapeutic challenge, as current treatment options provide limited long-term benefits due to issues surrounding their effectiveness and associated adverse effects.
Livianna Carrieri, Anas Munir, Giusi Caragnano, Davide Guido, Grazia Serino, Emanuele Piccinno, Domenico Mastronardi, Giusy Bianco, Nicolò Schena, Raffaele Armentano, Francesco Dituri, Gianluigi Giannelli   +11 more
doaj   +1 more source

Comparative analysis of regorafenib-treated HCC cells and SR cells.

The Venn diagrams (A) show the numbers of DEmRNAs in regorafenib-treated HCC cells and SR cells. GO BP terms (upper panel) and KEGG pathways (bottom panel) enriched in genes in regorafenib-treated HCC cells (B) and regorafenib-treated SR cells (C ...
Bert Binas (170), Hae In Choi (7289870), Kyoung Hwa Jung (12481658), Young Gyu Chai (12481661), Junho Cha (1872532), Mina Baek (12481649), Sungkyoung Choi (5126510), Minjae Kim (6208052)   +7 more
core   +1 more source

Supplementary Figure Legends, Figures 1 - 4 from Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis

, 2014
PDF file - 301KB, Figure S1. Potential roles of transcription factors in PUMA induction by regorafenib in CRC cells. Figure S2. p65 mediates PUMA induction by regorafenib in CRC cells. Figure S3.
Dongshi Chen (14928785), Lin Zhang (8926), Jian Yu (141239), Liang Wei (216043)   +3 more
core   +1 more source

Regorafenib Induced Interstitial Pneumonia in a Patient With Refractory Rectal Cancer

Respirology Case Reports
Regorafenib, a multi‐targeted tyrosine kinase inhibitor (TKI), is indicated for refractory colorectal carcinoma, gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma (HCC).
Tomo Tsunoda, Yoshiyuki Oyama, Ryota Miyamoto, Taisuke Ito, Takuro Akashi, Kazuo Tsuchiya, Masaki Ikeda   +6 more
doaj   +1 more source

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids

Frontiers in Cell and Developmental Biology
Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide, with its incidence continuing to rise. Regorafenib, a multi-kinase inhibitor approved for palliative treatment, has been shown to extend survival in patients ...
Giulia Agostini, Giulia Agostini, Morgane Leprovots, Jérôme Jeandriens, Anne Lefort, Anne Lefort, Frédérick Libert, Frédérick Libert, Francesco Sclafani, Ingrid Langer, Alain Hendlisz, Marie-Isabelle Garcia   +11 more
doaj   +1 more source